Neurocode

Executive Summary

Neurocode is a CAP/CLIA-certified clinical neurodiagnostic laboratory based in San Francisco, specializing in blood-based biomarker assays for Alzheimer's disease and other neurodegenerative disorders, as well as live cell-based assays for neuroimmunological conditions such as myasthenia gravis. Founded in 2018, the company provides elite diagnostic solutions to healthcare professionals, leveraging cutting-edge technology to improve early detection and monitoring of neurological diseases. While still a private entity with limited disclosed financials, Neurocode occupies a niche but growing market segment, driven by increasing demand for minimally invasive diagnostic tools. Its focus on validated biomarkers and high-sensitivity assays positions it well for adoption in neurology practices and research settings.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch of Alzheimer's blood biomarker panel70% success
• Q4 2026Strategic partnership with a major hospital system or pharmaceutical company50% success
• Q1 2027FDA breakthrough device designation or CLIA certification expansion40% success